BioAdvance News

Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression

By WebmasterMay 7, 2012November 1st, 2024No Comments

Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression
Read more here

Previous PostNiiki Pharma to Present Final Phase I Clinical Data on Anti-Cancer Agent at ASCO
Next PostFDA Approves Amyvid™ (Florbetapir F 18 Injection) for Use in Patients